trial · primary record
Sacituzumab tirumotecan
Non-small Cell Lung Cancer (NSCLC)
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 550 |
| Primary completion | 2030-06-14 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT06305754 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:20.034Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06305754
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Sacituzumab tirumotecan · compound